The aim of this project is to validate a blood based risk stratification tool, combining existing and routinely available markers (apolipoprotein-a1, C-reactive protein) with age and gender that could be an additional diagnosis and prognosis tool for screening subjects at high-risk of SARS-Cov-2 infection (SI).
The 2 biomarkers have a published role in the SARS-Cov-2 infection, with normal values depending on age and gender. A score combining the values of the 2 assays, corrected by age and gender, will be correlated to the risk of SI.
The project will last 3 years.
The public health impact could be major, helping the clinicians stratifying the patients according to this novel risk score.